Implications for risk assessment of host factors causing large pharmacokinetic variations

• Published in: Toxicology and industrial health Vol. 1; no. 4; p. 135
• Main Author: Vesell, E S
• Format: Journal Article
• Language: English
• Published: England 01.12.1985
• Subjects: Environmental Pollutants - analysis; Environmental Pollutants - toxicity; Epidemiologic Methods; Genotype; HLA Antigens - genetics; Humans; Kinetics; Molecular Biology; Risk
• ISSN: 0748-2337
• DOI: 10.1177/074823378500100409

Normal human subjects vary widely in their capacity to eliminate many drugs and environmental chemicals. These variations range in magnitude from fourfold to fortyfold depending on the drug and the population studied. Pharmacogenetics deals with only one of many host factors responsible for these large pharmacokinetic differences. Age, sex, diet and exposure to other drugs and chemicals, including oral contraceptives, ethanol and cigarette smoking, can alter the genetically determined rate at which a particular subject eliminates drugs and environmental chemicals. These elimination rates, therefore, are dynamic and change even in the same subject with time and condition. Regulatory legislation has only recently begun to recognize this very broad spectrum of human susceptibility and the existence of multiple special subgroups of particularly sensitive subjects. In setting standards for environmental chemicals, EPA and NIOSH have attempted to protect the most sensitive humans and should be encouraged to continue this policy. For some drugs and environmental chemicals, the commonly used safety factor of 100 may be too low; for these chemicals large, interindividual pharmacokinetic variations produced by pharmacogenetic and other host factors may make a safety factor of 400 or 500 more adequate.